Lucinda Warren

CIK: 0002035620

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CUE

Cue Biopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

CUE
Cue Biopharma, Inc.
Apr 9, 2026
Award(A)
Stock Option (right to buy)
Direct
250K shares-
CUE
Cue Biopharma, Inc.
Sep 29, 2025
Award(A)
Stock Option (right to buy)
Direct
125K shares-
CUE
Cue Biopharma, Inc.
Mar 21, 2025
Award(A)
Stock Option (right to buy)
Direct
250K shares-
CUE
Cue Biopharma, Inc.
Sep 3, 2024
Award(A)
Stock Option (right to buy)
Direct
350K shares-

		Type	Shares	Price		Ownership
Apr 9, 2026	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	250,000	-	-	Direct
Sep 29, 2025	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	125,000	-	-	Direct
Mar 21, 2025	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	250,000	-	-	Direct
Sep 3, 2024	CUE Cue Biopharma, Inc.	Award(A) Stock Option (right to buy)	350,000	-	-	Direct

1-4 of 4 transactions

About Warren Lucinda

Warren Lucinda (SEC CIK 0002035620) files insider reports with the SEC as CHIEF BUSINESS OFFICER of Cue Biopharma, Inc. (CUE).

Signal8 holds 5 ownership filings by Warren Lucinda (1 Form 3, 4 Form 4), filed between Sep 5, 2024 and Apr 10, 2026. Those filings report 4 transactions, from Sep 3, 2024 to Apr 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Warren Lucinda's filings is in BOSTON, MA.

Recent filings by Warren Lucinda

Apr 9, 2026: Grant or award of CUE derivative securities (Form 4, code A).
Sep 29, 2025: Grant or award of CUE derivative securities (Form 4, code A).
Mar 21, 2025: Grant or award of CUE derivative securities (Form 4, code A).
Sep 3, 2024: Grant or award of CUE derivative securities (Form 4, code A).

Other insiders filing for Cue Biopharma, Inc. (CUE)

Ray Sumita, Chief Legal Compliance Officer
Meluzio Michael Vincent, VP, Prin. Accounting Officer
Lin Shao-Lee, Chief Executive Officer
Sarraf Pasha, Director
Garzone Pamela, Director
Ahlers James M, Chief Financial Officer

How to read Form 4 transaction codes